ClinicalTrials.Veeva

Menu

Cancer Panel From Blood of Lung Cancer Patients (CAPABLE)

Seoul National University logo

Seoul National University

Status

Unknown

Conditions

Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer Recurrent

Treatments

Diagnostic Test: MACROGEN Pan Cancer Panel (Tier 2)

Study type

Observational

Funder types

Other

Identifiers

NCT03235765
SNUBH-17-01

Details and patient eligibility

About

Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This study is aimed to to compare concordance rate between tissue based cancer panel analysis and blood based cancer panel analysis in lung cancer patients (both by NGS technique).

Full description

This study is comprised of two cohorts as below:

Cohort A: inoperable, untreated, non-small cell lung cancer patients

Cohort B: non-small cell lung cancer patients who are in the treatment with targeted agents including immune checkpoint inhibitors

Enrollment

200 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Provision of informed consent prior to any study specific procedures, sampling, and analyses

  • Pathologically confirmed non-small cell lung cancer

  • Male or female, aged at least 20 years

  • Matches one of two criteria :

    1. Cohort A: Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
    2. Cohort B: Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.

Exclusion criteria

  • Any concurrent and/or other active malignancy that has required treatment within 3 years
  • Patients with mixed small cell histology
  • Life expectancy less than 3 months
  • Insufficient tissue for NGS test

Trial design

200 participants in 2 patient groups

Cohort A
Description:
Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
Treatment:
Diagnostic Test: MACROGEN Pan Cancer Panel (Tier 2)
Cohort B
Description:
Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
Treatment:
Diagnostic Test: MACROGEN Pan Cancer Panel (Tier 2)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems